MetaVia DA-1726 Higher-Dose Phase 1 EASL 2026 Late-Breaking Poster: 48 mg Cohort Safety, Tolerability, Pharmacokinetics + Exploratory Noninvasive Liver Assessment in GLP-1/Glucagon Dual Oxyntomodulin Analog
MetaVia presented late-breaking Phase 1 data on DA-1726 at the EASL Congress 2026 today in Barcelona. The poster titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment' covers the 48 mg dose level. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for obesity and MASH. The 4-week Phase 1 MAD trial earlier in 2026 documented compelling weight loss with best-in-class potential glucose control (GLP-1R arm), waist reduction (GCGR arm), and tolerability profile. The current 16-week Phase 1 Part 3 titration study is designed to optimize higher-dose levels and tolerability with full data expected Q4 2026. The EASL poster extends the early-phase MASH biomarker package and supports the planned Phase 2 advancement.